Nano-X Imaging Ltd. (NASDAQ: NNOX) is advancing its commercial and technology strategy for Nanox.AI through two developments that could expand the use of artificial intelligence in medical imaging. The company announced an exclusive three-year reseller agreement with Vertec Scientific, including minimum annual license commitments, establishing a dedicated UK channel for HealthOST, an AI-powered software solution that provides qualitative and quantitative analysis of spinal CT images to help clinicians evaluate spinal musculoskeletal disease, including osteoporosis. Separately, Nanox.AI has optimized its imaging AI framework for Intel Core Ultra processors using OpenVINO, demonstrating the potential to run AI inference locally on hospital hardware and reduce reliance on cloud connectivity.
These moves matter because they address two persistent barriers to AI adoption in radiology: commercial reach and deployment flexibility. The Vertec agreement gives Nanox.AI a dedicated UK channel with committed license volumes, which could accelerate revenue generation and market penetration for HealthOST. The technical optimization means hospitals may be able to run AI analysis on existing hardware without sending sensitive patient data to the cloud, potentially lowering costs and addressing data sovereignty concerns. Together, the developments support Nanox.AI’s strategy of extracting additional clinical value from already performed scans while offering healthcare providers more flexible deployment options.
For investors, the announcements signal progress on both the commercial and technological fronts for Nano-X Imaging Ltd. (NASDAQ: NNOX) (“Nanox”). The company’s broader ecosystem includes Nanox.ARC, a cost-effective 3D multi-source digital tomosynthesis imaging system; Nanox.AI; Nanox.CLOUD; and teleradiology services through USARAD Holdings. More information is available at www.Nanox.vision. The full article can be viewed at https://ibn.fm/eBRgx, and the latest news and updates relating to NNOX are available in the company’s newsroom at https://ibn.fm/NNOX.
The announcements were distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. For full terms of use and disclaimers applicable to all content provided by BioMedWire, see https://www.BioMedWire.com/Disclaimer.
